Article Text

Download PDFPDF

Paper
The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction
  1. Nir Eyal
  1. Correspondence to Professor Nir Eyal, Department of Global Health and Population, Harvard TH Chan School of Public Health, 651 Huntington Ave., FXB Building, Boston, MA 02139, USA; neyal{at}hsph.harvard.edu

Abstract

This piece introduces the JME symposium ‘The benefit/risk ratio challenge in clinical research, and the case of HIV cure.’

  • HIV Infection and AIDS
  • Research Ethics
  • Ethics

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This work was funded by NIAID grants 1 R01 AI114617-01A1 and 1 R56 AI114617-01, both titled ‘HIV cure studies: risk, risk perception, and ethics’.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles